Development
SpringWorks Therapeutics, Inc.
SWTX
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 5.45M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.45M | -- | -- | -- | -- |
| Cost of Revenue | 422.00K | -- | -- | -- | -- |
| Gross Profit | 5.03M | -- | -- | -- | -- |
| SG&A Expenses | 197.55M | 178.24M | 167.37M | 151.36M | 134.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 348.46M | 323.00M | 310.75M | 296.90M | 280.67M |
| Operating Income | -343.01M | -323.00M | -310.75M | -296.90M | -280.67M |
| Income Before Tax | -325.10M | -304.96M | -297.91M | -289.04M | -277.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -325.10 | -304.96 | -297.91 | -289.04 | -277.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -325.10M | -304.96M | -297.91M | -289.04M | -277.42M |
| EBIT | -343.01M | -323.00M | -310.75M | -296.90M | -280.67M |
| EBITDA | -341.35M | -321.62M | -309.64M | -295.99M | -279.91M |
| EPS Basic | -5.14 | -4.89 | -4.99 | -5.14 | -5.23 |
| Normalized Basic EPS | -3.21 | -3.05 | -3.12 | -3.22 | -3.27 |
| EPS Diluted | -5.14 | -4.89 | -4.99 | -5.14 | -5.23 |
| Normalized Diluted EPS | -3.21 | -3.05 | -3.12 | -3.22 | -3.27 |
| Average Basic Shares Outstanding | 252.65M | 249.58M | 239.96M | 226.57M | 213.18M |
| Average Diluted Shares Outstanding | 252.65M | 249.58M | 239.96M | 226.57M | 213.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |